Information:
Fel:
ID
24803
Beskrivning
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug; ODM derived from: https://clinicaltrials.gov/show/NCT00478595
Länk
https://clinicaltrials.gov/show/NCT00478595
Nyckelord
Versioner (1)
- 2017-08-18 2017-08-18 -
Uppladdad den
18 augusti 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Obesity NCT00478595
Eligibility Obesity NCT00478595
- StudyEvent: Eligibility
Similar models
Eligibility Obesity NCT00478595
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral | Sulfonylurea | alpha-Glucosidase Inhibitors
Item
type 2 diabetes mellitus patients on monotherapy with oral anti-diabetic drug (sulfonylurea or α-glucosidase inhibitor)
boolean
C0011860 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0038766 (UMLS CUI [3])
C1299007 (UMLS CUI [4])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0038766 (UMLS CUI [3])
C1299007 (UMLS CUI [4])
Glycosylated hemoglobin A
Item
hba1c ≥ 7.0 % and ≤ 10.0 %
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
body mass index ≥ 25 kg/m²
boolean
C1305855 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
Antidiabetics Oral | Exception Sulfonylurea | Exception alpha-Glucosidase Inhibitors | Insulin | Anti-Obesity Agents | Weight-Loss Agents
Item
within 12 weeks prior to screening visit: use of oral antidiabetic drugs (other than a sulfonylurea or alpha-glucosidase inhibitor) and/or insulin, of anti-obesity drugs or other drugs for weight reduction
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0038766 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1299007 (UMLS CUI [3,2])
C0021641 (UMLS CUI [4])
C0376607 (UMLS CUI [5])
C0376606 (UMLS CUI [6])
C1527415 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0038766 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1299007 (UMLS CUI [3,2])
C0021641 (UMLS CUI [4])
C0376607 (UMLS CUI [5])
C0376606 (UMLS CUI [6])
CORTICOSTEROIDS FOR SYSTEMIC USE Active Long-term | CORTICOSTEROIDS FOR SYSTEMIC USE Intake Prolonged | Lipid-lowering therapy Change
Item
within 4 weeks prior to screening visit: administration of systemic long-acting corticosteroids or prolonged use (more than one week) of other systemic corticosteroids, change in lipid lowering treatment
boolean
C3653708 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0443252 (UMLS CUI [1,3])
C3653708 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C0439590 (UMLS CUI [2,3])
C0585943 (UMLS CUI [3,1])
C0392747 (UMLS CUI [3,2])
C0205177 (UMLS CUI [1,2])
C0443252 (UMLS CUI [1,3])
C3653708 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C0439590 (UMLS CUI [2,3])
C0585943 (UMLS CUI [3,1])
C0392747 (UMLS CUI [3,2])
secondary obesity
Item
secondary obesity
boolean
C2062945 (UMLS CUI [1])
Hyperlipidemia Primary
Item
primary hyperlipidemia
boolean
C0020473 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,2])
Childbearing Potential Serum pregnancy test positive
Item
positive serum pregnancy test in females of childbearing potential
boolean
C3831118 (UMLS CUI [1,1])
C0430063 (UMLS CUI [1,2])
C0430063 (UMLS CUI [1,2])
Study Subject Participation Status
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])